Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442662 | 0.84 | BUB1 (0.37) | GPR119PIK3CAMTORPIM1PIM2 | |
| SCHEMBL19664854 | 0.84 | KMO (0.42) | KMOHDAC1 | |
| SCHEMBL8443691 | 0.82 | GPR119 (0.44) | GPR119BUB1MMP13 | |
| SCHEMBL3400140 | 0.77 | PIM1 (0.40) | PIK3CAMTORPIM1PIM2PLK1 | |
| SCHEMBL30684862 | 0.77 | PIM1 (0.40) | PIK3CAMTORPIM1PIM2PLK1 | |
| SCHEMBL10209788 | 0.74 | PIM1 (0.41) | GPR119PIK3CAMTORPIM1PIM2 | |
| SCHEMBL8443924 | 0.71 | BUB1 (0.44) | GPR119PIM1PIM2BUB1 | |
| SCHEMBL28169327 | 0.70 | CSNK1E (0.36) | KMO | |
| SCHEMBL17984900 | 0.69 | HRH3 (0.41) | — | |
| SCHEMBL8442660 | 0.69 | USP30 (0.39) | PIM1PIM2BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3252059-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | Medshine Discovery Inc. (CN) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252059-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | Medshine Discovery Inc. (CN) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016119706-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | 南京明德新药研发股份有限公司 | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | NDUFV1, NDUFV2, MT-ND4 | GPR119 3816/4885PIK3CA 4069/4885MTOR 1964/4885 |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | NDUFV1, NDUFV2, MT-ND4 | GPR119 3816/4885PIK3CA 4069/4885MTOR 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.